Cancers (Dec 2021)

Identification of Lynch Syndrome Carriers among Patients with Small Bowel Adenocarcinoma

  • Ariadna Sánchez,
  • Luis Bujanda,
  • Miriam Cuatrecasas,
  • Alex Bofill,
  • Cristina Alvarez-Urturi,
  • Goretti Hernandez,
  • Lara Aguilera,
  • Sabela Carballal,
  • Joan Llach,
  • Cristina Herrera-Pariente,
  • Mar Iglesias,
  • Liseth Rivero-Sánchez,
  • Gerhard Jung,
  • Lorena Moreno,
  • Teresa Ocaña,
  • Carolina Bayarri,
  • Maria Pellise,
  • Antoni Castells,
  • Sergi Castellví-Bel,
  • Francesc Balaguer,
  • Leticia Moreira

DOI
https://doi.org/10.3390/cancers13246378
Journal volume & issue
Vol. 13, no. 24
p. 6378

Abstract

Read online

Background: Small bowel adenocarcinoma (SBA) is a rare disease which can be associated with Lynch syndrome (LS). LS tumors are characterized by the presence of microsatellite instability (MSI) and/or the loss of mismatch repair (MMR) protein expression. In SBA, the frequency of MMR deficient (MMRd) tumors varies from 5% to 35%. This study aims to describe the prevalence of LS carriers among patients with MMRd small bowel adenocarcinomas. Methods: A multicenter retrospective study with identification and MMR testing of all consecutive SBA between 2004 and 2020 in a multicenter Spanish study. Demographical data, tumor characteristics, follow-up and survival information were collected. Germline testing was driven by identification of MMRd tumors. Results: A total of 94 individuals diagnosed with SBA were recruited. We observed 20 (21.3%) MMRd tumors. In 9/15 (60%) patients with MMRd tumors, a pathogenic variant was identified (three MLH1, four MSH2, one MSH6 and one PMS2). Accordingly, the prevalence of LS among all SBA cases was 10.1%. Conclusions: More than one-fifth of SBA display MMRd and in more than a half is due to LS. Our data supports the implementation of universal MMR tumor testing among SBA for the identification of LS families.

Keywords